BioSante Pharma concludes patient recruitment in LibiGel Phase III trial
The company is developing LibiGel as a treatment for female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women. The enrollment of the patients has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.